# Relationship between sleep disorders and the efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer

## TL;DR

This study shows that sleep disorders in older lung cancer patients receiving immune therapy are linked to worse treatment outcomes and more side effects.

## Contribution

The study is the first to show a link between sleep disorders and immune therapy outcomes in older non-small cell lung cancer patients.

## Key findings

- Sleep disorders reduced the chance of positive treatment response in patients receiving immune checkpoint inhibitors.
- Patients with sleep disorders had higher risks of gastrointestinal, liver, and lung toxicity.
- Sleep disorders were associated with lower survival rates and faster disease progression over 24 months.

## Abstract

Immune checkpoint inhibitors (ICIs) represent a critical treatment modality for older adults with advanced non-small cell lung cancer (NSCLC). The objective of this study was to investigate the potential relationship between sleep disorders, a condition commonly observed in this older population, and the efficacy of ICIs in treating advanced NSCLC.

A total of 495 older patients with NSCLC who had distant metastases or local infiltration and were ineligible for surgical resection were consecutively enrolled in the study. All patients received either ICI monotherapy or combination therapy, and were followed up for 24 months. Sleep quality was assessed four times using the Pittsburgh Sleep Quality Index to assess the average severity of sleep disorders. Treatment conditions, clinical outcomes, and Grade 3–4 adverse events were documented, and associations were evaluated using multivariate logistic regression or Cox regression analysis.

Sleep disorders were associated with a reduced likelihood of achieving complete response/partial response/stable disease for ICI efficacy at 3 months (P = 0.002), an increased risk of gastrointestinal, liver, and lung toxicity over the 24-month follow-up (P = 0.014, P = 0.012, P = 0.036), and a decreased probability of survival at 24 months (P = 0.004). Sleep disorders were also associated with reduced progression-free survival and overall survival during the 24 months (P = 0.048, P = 0.002).

Among older NSCLC patients receiving ICI treatment, sleep disorders are significantly associated with poorer treatment efficacy and a higher risk of multisystem adverse reactions. The findings of this study provide preliminary evidence for integrating sleep assessment into individualized ICI treatment strategies in this population.